Are these 3 ASX shares the next biotech blockbusters?

Here are three shares that are looking to follow in the footsteps of $60 billion biotech giant CSL Limited (ASX:CSL)…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of my favourite companies on the ASX would have to be biotech giant CSL Limited (ASX: CSL).

Thanks largely to its successful immunoglobulin business, CSL has grown into a $60 billion industry behemoth in the last decade.

Three shares which are aiming to follow in CSL's footsteps are listed below. Could they be future biotech stars?

Bionomics Ltd (ASX: BNO)

Last year this fledgling biotech company released positive Phase II trial results of its BNC210 anxiety drug. BNC210 not only outperformed the current standard of care, but also exhibited no signs of sedation, memory impairment, addiction, or loss of motor co-ordination. Management has forecast the global therapeutic market for the treatment of anxiety to be worth US$18.2 billion by 2020. If BNC210 can one day become the standard of care for anxiety treatment then Bionomics will profit greatly. But there is still a lot of hard work to come before that is potentially a reality.

Cynata Therapeutics Ltd (ASX: CYP)

Another exciting biotech company I think is worth taking a closer look at is stem cell and regenerative medicine company Cynata. The company's impressive Cymerus technology is able to produce an unlimited number of high quality stem cells at a low cost. These stem cells can then be used to treat numerous diseases including Graft versus Host Disease (GvHD) and cardiovascular disease. Major shareholder FUJIFILM has an exclusive worldwide license to market and sell its therapeutic MSC product CYP-001 for the treatment of GvHD.

Opthea Ltd (ASX: OPT)

Earlier this year Opthea released positive results from the Phase 1/2A clinical trial of its novel therapy OPT-302. The wet age-related macular degeneration therapy showed clinical activity in all patient groups investigated, including naïve and prior-treated patients. Another positive was that the strong result allowed the company to raise $42 million at a significant premium. This puts Opthea in a strong position to expand the clinical development of the potentially lucrative therapy. There is still a long way to go, but Opthea is a company I'll be keeping a close eye on.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »